Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HINT1 | P49773 | 5/20 | 0.58 |
| ▸ | NT5E | P21589 | 2/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 2/20 | 0.57 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | PNP | P00491 | 2/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL29045171 | 0.97 | HPGD (0.60) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL8995759 | 0.95 | HPGD (0.62) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL936682 | 0.93 | HPGD (0.55) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL9138605 | 0.92 | HPGD (0.58) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL24049416 | 0.90 | HPGD (0.76) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL24049417 | 0.90 | HPGD (0.76) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL11986902 | 0.90 | HPGD (0.76) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL24049467 | 0.90 | HPGD (0.76) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL20750695 | 0.90 | HPGD (0.76) | HPGDHINT1NT5EPAX8GSK3A | |
| Guanosine SCHEMBL413586 | 0.90 | HPGD (0.76) | HPGDHINT1NT5EPAX8GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116194780-A | Method for detecting beta-sheet aggregate form of protein forming beta-sheet aggregate | CISBIO生物试验公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230091315-A1 | ANTI-G-PROTEIN ALPHA ANTIBODY | CISBIO BIOASSAYS (FR) | 2023-03-23 | — | — | US | disclosed |
| CN-115397858-A | anti-G protein alpha antibody | CISBIO生物试验公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-3658913-A1 | METHOD FOR MEASURING MODULATION IN THE ACTIVITY OF A G PROTEIN-COUPLED RECEPTOR | CISBIO BIOASSAYS (FR) | 2020-06-03 | — | — | EP | disclosed |
| CN-105497701-A | Natural medicine for treating gout diseases and preparation method thereof | DU ZHIZHENG | 2016-04-20 | — | — | CN | disclosed |
| CN-104940449-A | Medicine for treating gout | LUO CAILIAN | 2015-09-30 | — | — | CN | disclosed |
| CN-103142655-B | Composite probiotics for treating podagra and preparation method thereof | XUE SONGXIAO (CN) | 2014-10-29 | — | — | CN | disclosed |
| EP-2087355-B1 | METHOD FOR THE DETECTION OF POST-TRANSLATIONAL MODIFICATIONS | CISBIO BIOASSAYS (FR) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014063703-A1 | MONOCLONAL ANTIBODIES | STATENS SERUM INSTITUT (DK) | 2014-05-01 | — | — | WO | disclosed |
| US-8663928-B2 | Method for the detection of post-translational modifications | CIS BIO INTERNATIONAL (FR) | 2014-03-04 | — | — | US | disclosed |
| US-5675063-A | EXPRESSES TWO ONCOGENES AND IS CAPABLE OF FUSING WITH ACTIVATED B-LYMPHOCYTE RESULTING IN HYBRIDOMA THAT PRODUCES IMMUNOGLOBULINS | LOYOLA UNIVERSITY OF CHICAGO (US) | 1997-10-07 | — | — | US | disclosed |
| US-5573920-A | Antibodies, and methods for their use | SURFACE ACTIVE LIMITED (GB) | 1996-11-12 | — | — | US | disclosed |
| EP-0511011-B1 | Novel antibodies and methods for their use | SURFACE ACTIVE LTD (GB) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996027004-A1 | AN IMMORTALIZED MAMMAL HYBRIDOMA FUSION PARTNER | LOYOLA UNIVERSITY OF CHICAGO (US) | 1996-09-06 | — | — | WO | disclosed |
| US-5527895-A | CLEAVE SPECIFIC RNA SEQUENCES INTO A FRAGMENT HAVING A 5'HYDROXYL AND A FRAGMENT HAVING A 2',3'CYCLIC PHOSPHATE; PRODUCTS RESEMBLE THOSE RESULTING FROM THE NATURAL HYDROLYSIS OF RNA | THE BOARD OF REGENTS FOR NORTHERN ILLINOIS UNIVERSITY OF DEKALB (US) | 1996-06-18 | — | — | US | disclosed |
| EP-0666749-A1 | ENANTIOMERICALLY PURE beta-D-DIOXOLANE NUCLEOSIDES WITH SELECTIVE ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994009793-A1 | ENANTIOMERICALLY PURE β-D-DIOXOLANE NUCLEOSIDES WITH SELECTIVE ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0582595-A1 | NOVEL ANTIBODIES, AND METHODS FOR THEIR USE | SURFACE ACTIVE LIMITED (GB) | 1994-02-16 | — | — | EP | disclosed |
| WO-1992019973-A1 | NOVEL ANTIBODIES, AND METHODS FOR THEIR USE | SURFACE ACTIVE LIMITED (GB) | 1992-11-12 | — | — | WO | disclosed |
| EP-0511011-A1 | Novel antibodies and methods for their use | SURFACE ACTIVE LIMITED (GB) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091315-A1 | ANTI-G-PROTEIN ALPHA ANTIBODY | GNG2, GNAI3, GNAI2 | HPGD 4428/4885HINT1 683/4885NT5E 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.